- RecruitingPHASE3
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Upadacitinib for children and teenagers with Crohn's disease. It's for those whose current treatments aren't working well. We want to see if it's safe and helps them feel better.
For: Crohn's DiseaseUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
This study looks at combining two medicines, vedolizumab and upadacitinib, for adults with moderate to severe Crohn's Disease. It aims to see if this combination better reduces bowel inflammation and ulcers compared to vedolizumab alone, and to check its safety.
For: Crohn's DiseaseUnited States · Austria · Belgium - RecruitingPHASE3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
This study looks at a daily tablet called upadacitinib for severe alopecia areata, a condition where your immune system attacks hair follicles, causing hair loss. It aims to see how safe and effective it is for teenagers and adults.
For: Alopecia AreataUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.
For: Rheumatoid ArthritisUnited States · Argentina · Belgium - Active not recruitingPHASE3
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
This study looks at a medicine called Upadacitinib for children and young people aged 2-17 with moderate to severe ulcerative colitis. It aims to see how safe and effective the medicine is, how it works in the body, and if it helps reduce symptoms.
For: Ulcerative ColitisUnited States · Australia · Belgium - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
For: Systemic Lupus ErythematosusUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
This study looks at a new medicine called Upadacitinib for children aged 2-17 with a type of arthritis called Juvenile Idiopathic Arthritis (JIA). We're checking how the medicine works in their bodies, if it's safe, and if they can tolerate it.
For: Juvenile Idiopathic Arthritis (JIA)United States · Canada · Germany - Active not recruitingPHASE3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
This study looks at a new combination treatment for teenagers and adults with moderate to severe eczema. It combines a new tablet called upadacitinib with steroid creams to see how well it works and if it's safe.
For: Atopic DermatitisUnited States · Australia · Austria - RecruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
For: Hidradenitis SuppurativaUnited States · Argentina · Australia - Recruiting
Molecular Signatures in Inflammatory Skin Disease
This study looks at people with skin conditions like eczema and psoriasis to understand how their bodies respond to new treatments. We want to find patterns in their genes and cells to help doctors choose the best medicine for each person in the future.
For: Atopic Dermatitis · PsoriasisGermany - RecruitingPHASE3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This study looks at two medicines, upadacitinib and dupilumab, for children aged 2 to 11 with moderate to severe eczema (atopic dermatitis). It wants to see which one works better and has fewer side effects for children who need strong treatment.
For: Atopic DermatitisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
For: Crohn's DiseaseUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
This study looks into a new tablet medicine, upadacitinib, for adults and teenagers with a type of vitiligo. Researchers want to see how safe it is and how well it helps improve skin when compared to a dummy pill or light therapy.
For: VitiligoUnited States · Argentina · Belgium - Not yet recruitingPHASE2
Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.
This study is testing a new medicine, Upadacitinib, for people with severe forms of lichen planus that affect the mouth, other moist areas, or the scalp, causing hair loss. It aims to see if this medicine can help reduce symptoms and improve quality of life.
For: Lichen Penis PlanusFrance - RecruitingPHASE3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
This study looks at new treatments for a severe type of childhood arthritis called Systemic Juvenile Idiopathic Arthritis (sJIA). It compares upadacitinib with an existing treatment, tocilizumab, to see how well they work and if they cause any side effects in children aged 1 to 17.
For: Juvenile Idiopathic ArthritisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
For: Rheumatoid ArthritisUnited States · Argentina · Australia